Reports Q4 revenue $709,000, consensus $250,000. "We continue to make great progress in our vision to build a premier, fully integrated endocrine company that can sustainably innovate pioneering therapies for our patients around the world," said Scott Struthers, founder and chief executive officer of Crinetics. "In 2022, we demonstrated pharmacologic proof-of-concept for CRN04894 and CRN04777, established global clinical study capabilities with our Phase 3 PATHFNDR program for paltusotine in acromegaly, and began laying groundwork for a potential commercial launch."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CRNX:
- Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
- Crinetics to present corporate, clinical update at JPMorgan conference
- Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference